DE60326153D1 - Verfahren zur diagnose von morbus alzheimer - Google Patents
Verfahren zur diagnose von morbus alzheimerInfo
- Publication number
- DE60326153D1 DE60326153D1 DE60326153T DE60326153T DE60326153D1 DE 60326153 D1 DE60326153 D1 DE 60326153D1 DE 60326153 T DE60326153 T DE 60326153T DE 60326153 T DE60326153 T DE 60326153T DE 60326153 D1 DE60326153 D1 DE 60326153D1
- Authority
- DE
- Germany
- Prior art keywords
- diagnosis
- subject
- methods
- present
- morbus alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40001602P | 2002-07-30 | 2002-07-30 | |
| PCT/US2003/023093 WO2004011943A1 (en) | 2002-07-30 | 2003-07-24 | Method of diagnosing alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60326153D1 true DE60326153D1 (de) | 2009-03-26 |
Family
ID=31188657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60326153T Expired - Lifetime DE60326153D1 (de) | 2002-07-30 | 2003-07-24 | Verfahren zur diagnose von morbus alzheimer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7682795B2 (de) |
| EP (1) | EP1543331B1 (de) |
| AT (1) | ATE422671T1 (de) |
| AU (1) | AU2003259222A1 (de) |
| DE (1) | DE60326153D1 (de) |
| WO (1) | WO2004011943A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| RU2006122946A (ru) | 2003-11-28 | 2008-01-10 | Астразенека Аб (Se) | Антитела |
| US7612179B2 (en) | 2003-11-28 | 2009-11-03 | Astrazeneca Ab | antibodies binding to a C-terminal fragment of apoliopoprotein E |
| WO2006110621A2 (en) * | 2005-04-11 | 2006-10-19 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject |
| AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| RS53270B2 (sr) | 2005-11-30 | 2018-05-31 | Abbvie Deutschland | Monoklonalna antitela protiv amiloidnog beta proteina i njihova upotreba |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20090136456A1 (en) * | 2006-12-22 | 2009-05-28 | Yadong Huang | Methods of treating neurodegenerative disorders |
| EP2486928A1 (de) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Verfahren zur Behandlung von Amyloidosen |
| WO2009062152A1 (en) * | 2007-11-09 | 2009-05-14 | Washington University In St. Louis | Methods for measuring the metabolism of cns derived biomolecules in vivo |
| WO2011109246A1 (en) * | 2010-03-01 | 2011-09-09 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
| MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
| WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9488666B2 (en) | 2010-08-24 | 2016-11-08 | Helena Laboratories Corporation | Assay for determination of levels of lipoprotein particles in bodily fluids |
| US8741298B2 (en) | 2011-02-07 | 2014-06-03 | Neotope Biosciences Limited | APOE immunotherapy |
| EP3760235A1 (de) | 2014-09-30 | 2021-01-06 | Washington University | Kinetische tau-messungen |
| CA2975059C (en) * | 2015-01-29 | 2023-02-21 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| US6287793B1 (en) | 1988-08-19 | 2001-09-11 | Elan Pharmaceuticals, Inc. | Diagnostic methods for alzheimer's disease |
| WO1993003369A1 (en) | 1991-08-01 | 1993-02-18 | Voorheis Paul H | Diagnostic method for alzheimer's disease |
| CA2086165A1 (en) | 1992-04-09 | 1993-10-10 | Paul P. Tamburini | Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein |
| WO1994009371A1 (en) | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Antemortem diagnostic test for alzheimer's disease |
| NZ257215A (en) | 1992-10-13 | 1996-12-20 | Univ Duke | Diagnosis or prognosis of alzheimers using the presence of apolipoprotein e type 4 as an indicator and apolipoprotein e isoform specific antibodies |
| US6300085B1 (en) | 1993-05-03 | 2001-10-09 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic method for Alzheimer's disease |
| US5849600A (en) | 1993-11-10 | 1998-12-15 | The Mclean Hospital Corporation | Diagnostic assays for Alzheimer's disease |
| FR2716894B1 (fr) | 1994-03-07 | 1996-05-24 | Pasteur Institut | Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic. |
| US5976798A (en) | 1994-03-30 | 1999-11-02 | Mitokor | Methods for detecting mitochondrial mutations diagnostic for Alzheimer's disease and methods for determining heteroplasmy of mitochondrial nucleic acid |
| US5972634A (en) | 1994-10-19 | 1999-10-26 | The General Hospital Corporation | Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities |
| US5817789A (en) * | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US5976817A (en) | 1996-10-31 | 1999-11-02 | Trustees Of Boston University | Diagnostic method for detecting Alzheimer's disease in living patients |
| US6183981B1 (en) | 1998-03-05 | 2001-02-06 | Board Of Regents, The University Of Texas System | Diagnostic assay for late-onset Alzheimer's disease |
| DE60134430D1 (de) * | 2000-11-03 | 2008-07-24 | David Gladstone Inst | Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe |
| US6766817B2 (en) | 2001-07-25 | 2004-07-27 | Tubarc Technologies, Llc | Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action |
-
2003
- 2003-07-24 WO PCT/US2003/023093 patent/WO2004011943A1/en not_active Application Discontinuation
- 2003-07-24 DE DE60326153T patent/DE60326153D1/de not_active Expired - Lifetime
- 2003-07-24 EP EP03771762A patent/EP1543331B1/de not_active Expired - Lifetime
- 2003-07-24 US US10/627,447 patent/US7682795B2/en not_active Expired - Fee Related
- 2003-07-24 AU AU2003259222A patent/AU2003259222A1/en not_active Abandoned
- 2003-07-24 AT AT03771762T patent/ATE422671T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1543331A1 (de) | 2005-06-22 |
| EP1543331B1 (de) | 2009-02-11 |
| EP1543331A4 (de) | 2006-08-02 |
| AU2003259222A1 (en) | 2004-02-16 |
| US20040157267A1 (en) | 2004-08-12 |
| ATE422671T1 (de) | 2009-02-15 |
| WO2004011943A1 (en) | 2004-02-05 |
| US7682795B2 (en) | 2010-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60326153D1 (de) | Verfahren zur diagnose von morbus alzheimer | |
| ATE386942T1 (de) | Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer | |
| DE60233485D1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| DE60016178D1 (de) | Verfahren zur diagnose und zur charakterisierung von schlaganfall | |
| DE69840154D1 (de) | Verfahren zur Diagnose der Alzheimer Erkrankung auf der Basis eines Gen Transkriptionsmusters | |
| WO2005098433A3 (en) | Diagnostic assays for alzheimer’s disease | |
| DE60325617D1 (de) | Verfahren zur diagnose von bauchspeicheldrüsenkrebs | |
| DE602005022924D1 (de) | Verfahren zur diagnose von morbus crohn | |
| ATE493649T1 (de) | Verfahren zur diagnose von polyzystischer nierenkrankheit | |
| ATE514948T1 (de) | In vitro verfahren zur diagnose von neurodegenerativen erkrankungen | |
| ATE523788T1 (de) | ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN | |
| DE60332538D1 (de) | Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen | |
| ATE483982T1 (de) | Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen | |
| ATE406579T1 (de) | Verfahren zur diagnose von tumoren | |
| DE60325382D1 (de) | Verfahren zur diagnose von gebärmutterhalskrebs | |
| ATE480641T1 (de) | Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes | |
| DE60333195D1 (de) | Verfahren zur diagnose des myokardinfarktrisikos | |
| ATE465408T1 (de) | Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins | |
| DE50007635D1 (de) | Verfahren zur diagnose von sjögren-syndrom | |
| BR0111975A (pt) | Fator, composição, veìculo, ligando, kits de diagnósticos, processos para detectar uma prpsc em uma amostra, e para remover prpsc de material biológico, método para diagnosticar encefalopatias espongiformes humanas transmissìveis e encefalopatias de prìons de animais, e, uso de um fator | |
| ATE509271T1 (de) | Verfahren zur diagnose von myasthenia gravis | |
| WO2003104812A3 (en) | DIAGNOSIS ASSAY FOR ALZHEIMER'S DISEASE BASED ON THE DETERMINATION OF THE HA DOLLAR G (B) 42 RATE: HA DOLLAR G (B) 40 | |
| ATA19972000A (de) | Pibf für die diagnose von tumoren | |
| ATE302416T1 (de) | Auf holo-transcobalamin ii beruhendes diagnostisches verfahren für alzheimer-krankheit | |
| ATE397090T1 (de) | Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |